Announcements
- Treatment of XF-73 Nasal reduces antibiotic use
- Proposed Cancellation of Admission to Trading
- Exercise of Options and Total Voting Rights
- Efficacy of XF-70 in Fungal Skin Infections
- Result of Annual General Meeting
- 2024 Annual General Meeting and Statement
- Destiny Pharma's XF-73 Nasal Awarded MHRA ILAP
- Posting of Annual Report and Notice of AGM
- Full year results and review of strategic options
- Notice of Full Year Results
More ▼
Key statistics
On Monday, Destiny Pharma PLC (D89:FRA) closed at 0.032, 8.47% above its 52-week low of 0.0295, set on Jul 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.053 |
---|---|
High | 0.053 |
Low | 0.032 |
Bid | 0.0375 |
Offer | 0.042 |
Previous close | 0.047 |
Average volume | 0.00 |
---|---|
Shares outstanding | 95.77m |
Free float | 72.28m |
P/E (TTM) | -- |
Market cap | 4.07m GBP |
EPS (TTM) | -0.0624 GBP |
Data delayed at least 15 minutes, as of Jul 22 2024 14:29 BST.
More ▼